TuHURA Biosciences (HURA) to Release Quarterly Earnings on Wednesday

TuHURA Biosciences (NASDAQ:HURA) is expected to be releasing its results before the market opens on Wednesday, February 25th. Analysts expect TuHURA Biosciences to post earnings of ($0.1233) per share for the quarter.

TuHURA Biosciences Price Performance

NASDAQ:HURA opened at $1.24 on Tuesday. The firm has a market cap of $75.29 million, a PE ratio of -2.48 and a beta of 0.12. The firm has a 50 day simple moving average of $0.82 and a 200-day simple moving average of $1.82. TuHURA Biosciences has a 1-year low of $0.41 and a 1-year high of $4.44.

Institutional Trading of TuHURA Biosciences

A number of institutional investors have recently modified their holdings of the company. State Street Corp lifted its position in TuHURA Biosciences by 4.9% during the fourth quarter. State Street Corp now owns 289,133 shares of the company’s stock valued at $219,000 after buying an additional 13,594 shares in the last quarter. New York State Common Retirement Fund purchased a new position in shares of TuHURA Biosciences in the 2nd quarter valued at $97,000. Marshall Wace LLP purchased a new position in shares of TuHURA Biosciences in the 2nd quarter valued at $79,000. Jane Street Group LLC acquired a new position in shares of TuHURA Biosciences during the 1st quarter valued at $69,000. Finally, Deutsche Bank AG boosted its position in TuHURA Biosciences by 209.8% during the 4th quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock worth $61,000 after purchasing an additional 54,051 shares during the period. Hedge funds and other institutional investors own 0.62% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on HURA. Maxim Group cut their price target on TuHURA Biosciences from $15.00 to $8.00 and set a “buy” rating for the company in a report on Friday, November 14th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of TuHURA Biosciences in a research report on Tuesday, February 3rd. Wall Street Zen downgraded TuHURA Biosciences from a “hold” rating to a “sell” rating in a research report on Sunday, December 14th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $9.00.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.